Literature DB >> 16160007

Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation.

Barbara Plaimauer1, Jakob Fuhrmann, Gabriele Mohr, Waltraud Wernhart, Katharina Bruno, Silvia Ferrari, Christian Konetschny, Gerhard Antoine, Manfred Rieger, Friedrich Scheiflinger.   

Abstract

Sequence analysis of the ADAMTS13 locus of 2 patients with hereditary thrombotic thrombocytopenic purpura (TTP) revealed the homozygous presence of 4 single nucleotide polymorphisms (SNPs) (R7W, Q448E, P618A, A732V) and a rare missense mutation (R1336W). Analysis of the individual effect of any amino acid exchanges showed that several sequence variations can interact with each other, thereby altering the phenotype of ADAMTS13 deficiency. Introduction of polymorphisms R7W, Q448E, and A732V had no or only minor effects on ADAMTS13 secretion. In contrast, P618A, R1336W, and the A732V-P618A combination strongly reduced ADAMTS13-specific activity and antigen levels. Surprisingly, R7W and Q448E were positive modifiers of ADAMTS13 secretion in the context of P618A and A732V but neither could rescue the severely reduced specific activity conferred by P618A. However, in the context of R1336W, polymorphisms R7W and Q448E enhanced the detrimental effect of the missense mutation and led to undetectable enzyme activity. We show that dependent on the sequence context, the same polymorphisms might be either positive or negative modifiers of gene expression. Our results might therefore be widely relevant to understanding the influence of polymorphisms on the phenotypic expression of complex diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160007     DOI: 10.1182/blood-2005-06-2482

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

2.  Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome.

Authors:  Shuju Feng; Stephen J Eyler; Yuzhou Zhang; Tara Maga; Carla M Nester; Michael H Kroll; Richard J Smith; Vahid Afshar-Kharghan
Journal:  Blood       Date:  2013-07-11       Impact factor: 22.113

Review 3.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

4.  Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor.

Authors:  Masashi Akiyama; Soichi Takeda; Koichi Kokame; Junichi Takagi; Toshiyuki Miyata
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-30       Impact factor: 11.205

5.  Idiopathic noncirrhotic intrahepatic portal hypertension is associated with sustained ADAMTS13 Deficiency.

Authors:  Ian Mackie; C E Eapen; Desley Neil; Andrew S Lawrie; Andrew Chitolie; Jean C Shaw; Elwyn Elias
Journal:  Dig Dis Sci       Date:  2011-05-15       Impact factor: 3.199

6.  Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels.

Authors:  Qianyi Ma; Paula M Jacobi; Brian T Emmer; Colin A Kretz; Ayse Bilge Ozel; Beth McGee; Chava Kimchi-Sarfaty; David Ginsburg; Jun Z Li; Karl C Desch
Journal:  Blood Adv       Date:  2017-06-19

Review 7.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 8.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.

Authors:  Chantal Loirat; Jean-Pierre Girma; Céline Desconclois; Paul Coppo; Agnès Veyradier
Journal:  Pediatr Nephrol       Date:  2008-06-24       Impact factor: 3.714

Review 9.  Pathogenesis of thrombotic microangiopathies.

Authors:  X Long Zheng; J Evan Sadler
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

Review 10.  Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.

Authors:  Han-Mou Tsai
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.